AMERICAN NATUROPATHIC RESEARCH INSTITUTE
NATUROPATHIC ONCOLOGY RESEARCH INSTITUTE
1250 E. Baseline Rd., Suite 205
Tempe, AZ 85283
JOINT MEETING OF THE
AMERICAN NATUROPATHIC RESEARCH INSTITUTE (ANRI)
NATUROPATHIC ONCOLOGY RESEARCH INSTITUTE (NORI)
INTERNATIONAL NATUROPATHIC CLINICAL RESEARCH INSTITUTE
INSTITUTIONAL REVIEW BOARD (IRB)
May 4, 2018
MINUTES AND MEETING NOTES
In accordance with the requirements of the United States Code of Federal Regulations, Title 21, Chapter 1, Subchapter A, Part 56, the thirty-fourth regular quarterly meeting of the American Naturopathic Research Institute (ANRI) and the Naturopathic Oncology Research Institute (NORI) and the International Naturopathic Clinical Research Institute (INCRI) and the Institutional Review Board (IRB) was called to order at 12:00 p.m., May 4, 2018 at 1250 E. Baseline Rd., Suite 205, meeting in Suite 203, Tempe, AZ 85283.
MEMBERS AND GUESTS
14 members and guests were in attendance. This included 9 physicians and 5 non-physicians,
The meeting was called to order at 12:00 pm.
There is a possibility of a seminar regarding minerals and the cell membrane, by a researcher in this area. We will post the announcement, to try to maximize attendance.
Liver disease causes 2% of deaths worldwide. We discussed a treatment in which no side effects have been reported to date.
The medical community can be difficult. One patient’s GI doctor threatened her: “You better not take this treatment. Because if you do, we’ll take you off the liver transplant list.” (A liver transplant can bring in $500,000 to a hospital.)
Safety, purity and effectiveness were discussed. Questions were posed and answered.
A motion was made to approve this study for review by our IRB. That motion was seconded. We voted unanimously for approval for review of this study by our IRB.
Dr. Dickens pointed out that we are challenging a system, for the benefit of people. So our glory is in that satisfaction, and not much more in the way of accolades or material gain.
A physiotherapy treatment was discussed.
Questions arose regarding safety of the machine in use with patients.
Other questions arose:
What testing would be done, for initial status and monitoring response?
Other concerns raised were as follows:
Which patients will be included? What are the inclusion and exclusion criteria?
Also, some further information regarding the science behind this, and safety studies would be good. The endnotes on the emailed document are clickable. However, we requested that more information on the safety studies be provided.
We decided that this study is not quite ready for IRB review. We first need inclusion and exclusion criteria, specific uses, before and after monitoring, and above all, safety studies.
FDA ACTIVITIES AND CONGRESS’ RESPONSE TO THE SAME
We mentioned some of the recent anti-alternative medicine language in FDA Commissioner Scott Gottlieb’s recent comments. We also mentioned the very difficult environment that the FDA has recently created for compounding pharmacies.
Then we examined two recent documents from the US Congress, which state even more clearly than in 2015 that the FDA “must stop” its overreach in the compounding of medications.
We discussed a patient with a chronic case of Rasmussen’s encephalopathy, and autoimmune brain disease. Kids with this have massive brain seizures, as well as cognition and memory problems. They cannot access memory. In this particular case, there was a brain biopsy. Normally hemicephalotomy is the treatment. But in this patient, the problem was on his L side, governing the dominant side. He is greatly affected by diet and MSG and other chemicals. MSG, gluten, dairy massive grand mal seizures, mostly at night.
The treatment since 2005 has been anti-oxidant support. The patient was expected to regress to a vegetative state. Lamigdal produced some of the worst seizures ever. A neurologist said to the family, ‘if you don’t want drugs, why are you here?’
Then R sided symptoms started: R arm jerking, much pain. IV-H202 helped to a certain extent. Vit C IVs were not as effective. The focal seizures caused his shoulder to become worse. The patient was hospitalized for status epilepticus. Na levels stayed high, 155 or 159. Hydrating helps; there is no thirst. Keppra did not help. Last January, he started getting worse with some focal seizures. Then a grand mal. Then things got really quite a bit worse.
IV Lorazepam was the only thing that could disrupt that cycle usually. But this time it did not work. The patient kept seizing. 2 days later: IV Vimpat (Lacosamide) and Valproic acid. No matter what was given, the seizures kept getting worse. Then the seizures were “like a freight train.” Intubated in ICU settled with Versed and Phenobarbitol twilight or deeper coma. Had a low-grade fever since ER, a 99-degree axillary temp., then 100 to 101. Blood culture Klebsiella. Antibiotics Still had some seizures, but things finally settled down. Rx’ed Vimpat and Valproic acid. Then backed off of Vimpat, but still having right side issues. Valproic Ac more seizures. Reduced Valproic ac seizures improved.
One of the physicians present at our meeting, a pediatrician, addressed the case:
Barbiturates are lipophilic and remain in the brain for quite a long time. Phenobarbital has cognitive and memory effects. However, oral phenobarbital may be one of the most helpful drugs here. Likely, the patient was suffering withdrawal from phenobarbital. Another thought is dimethyl glycine for this patient? It has brain-stabilizing qualities. The more seizures, the worse for the brain over the long term, with the damage that occurs.
Has the patient ever been checked for EBV or CMV? He was first diagnosed in 2005. In mental illness as well as in cancer: often seen are fragments of EBV and CMV.
We discussed a natural treatment that has shown excellent effect against these.
The next meeting will be held on Friday, August 10, 2018 at noon, the usual place.